r/StockPickNews

I’ve been looking at Zoetis after the recent selloff, and I think it is an interesting value setup.

The simple question:
Is Zoetis facing a structural impairment in companion animal demand and pricing power, or is the market overreacting to a cyclical pet-care slowdown and a messy reset in expectations?

This used to be an easy pass for me.

At 30x+ earnings, Zoetis may have been a great business, but the valuation did not make much sense. At roughly 11x forward earnings, the question changes.

Zoetis is a global animal health company across medicines, vaccines, diagnostics, biodevices, genetic tests, and precision animal health. If you own a dog, you may know them through Simparica Trio.

The bear case is real:

- U.S. companion animal revenue declined 11% YoY
- vet clinic traffic is softer
- pet owners are more price-sensitive
- Credelio Quattro is a credible competitor to Simparica Trio
- dermatology is under pressure
- Librela remains an overhang
- management cut 2026 guidance

So I do not think the market is reacting to nothing. The question is whether this is a structural break or a reset in expectations.

The reason I am interested is that the quality profile still does not look broken:
- Gross margin around 70%
- Operating margin in the mid-30s
- ROE around 40%
- ROIC around 18%-20%
- ROCE around 20%+
- Forward payout ratio around 30%
- BBB+ credit rating
- Net debt/EBITDA around 1.65x
- Interest coverage around 15x

Those are not the numbers of a low-quality business or a financially stressed one.

My current view is that the Zoetis flywheel still looks largely intact: high margins, strong free cash flow, trusted veterinary distribution, R&D reinvestment, new products, pricing power, and then more cash to reinvest again.

The valuation is what makes it interesting to me.

Forward EPS expectations are roughly:

2026: $6.85-$7.00
2027: ~$7.40
2028: ~$7.96

If Zoetis can stabilize the business and eventually trade closer to 20x earnings, you can get to a materially higher stock price without assuming a return to the old 30x+ multiple.

That is the core thesis: Zoetis does not need to become expensive again. It just needs to prove the flywheel is not broken.

What would make me wrong:
If the pet-care slowdown is structural, if Zoetis loses share in key franchises, if pricing power fades, if Librela or other product issues damage trust with vets, or if the R&D pipeline fails to offset pressure in existing products, then the old margin and multiple structure probably no longer applies.

I think this can go very wrong or very right, which is usually where I start paying attention.

Curious how others are thinking about ZTS. Is this a broken compounder, or is the market pricing in too much permanent impairment?

Disclosure: I now own shares! Not investment advice.

In the article, Wendy’s is mentioned as an example of a stock that is well-positioned to withstand a market downturn.

​The author highlights Wendy's because it fits the criteria for the defensive investment strategy discussed in the study (which prioritizes low-volatility, high-yielding value stocks). The article suggests that for investors who are worried about a market decline but want to remain invested, stocks like Wendy’s offer better protection compared to more volatile, high-growth stocks.

Full article available here: https://www.barrons.com/articles/goldman-sachs-stock-sell-banks-analyst-downgrade-858eeb3c?regwall=eafs

If you are looking for stocks with momentum as well as those that might offer attractive value, here are the top 10 featuring stocks from Fidelity that are up at least 16.8% year to date, have a positive P/E-to-growth (PEG) ratio of 1.76 and below, and a 90-day daily volume average of at least 317.69K, sorted by market cap, as of June 25, 2026:

Taiwan Semiconductor (TSM)

Micron (MU)

Sandisk (SNDK)

GE Vernova (GEV)

Royal Bank of Canada (RY)

Dell (DELL)

Western Digital (WDC)

Citigroup (C)

Seagate Technology (STX)

Toronto-Dominion Bank (TD)

#stock #stockmarket